ENGLISH

Risk-sharing in the Pharmaceutical Industry: The Case of Out-licensing

By Dr. Gerrit Reepmeyer (auth.)

Book information

Publisher
Physica-Verlag Heidelberg
Year
2006
ISBN
978-3-7908-1667-9, 978-3-7908-1668-6
DOI
10.1007/3-7908-1668-X
Language
english
Format
PDF
Filesize
17 MB (18303400 bytes)
Series
Contributions to Management Science
Edition
1
Pages
297\305
Orientation
yes
Scanned
yes
Time added
2013-08-01 04:00:00
Technology Management

Description

The costs of developing a new drug have reached record levels in the pharmaceutical industry. As any failure of a new drug candidate can lead to significant losses, many pharmaceutical companies are looking for new approaches to reduce their exposure to R&D risks. In this context, the book deals with the topic of out-licensing as a novel form of risk-sharing collaborations. The phenomenon of out-licensing is illustrated by three major case studies of Novartis, Schering and Roche as well as several smaller case studies. In addition, the Noble Prize awarded economic theory of Adverse Selection is applied to analyze the topic theoretically. The gained insights allow identifying the critical parameters of out-licensing collaborations and thereby provide R&D managers with recommendations on how to conclude and manage this type of deals more effectively.

Similar books